Can you write an example follow‑up note documenting ECG monitoring for a 35‑year‑old male with treatment‑resistant schizophrenia on clozapine 300 mg daily, including baseline and current ECG findings, symptom review, laboratory results, and the management plan?

Example Follow-Up Note for Clozapine ECG Monitoring

For a patient on clozapine 300 mg daily, document baseline and current ECG findings (specifically QTc interval, heart rate, and any ST-T wave changes), vital signs with orthostatic measurements, cardiac symptoms (chest pain, palpitations, dyspnea), laboratory results including troponin and CRP if obtained, and the continuation plan with next monitoring timepoint.

Clinical Documentation Template

Patient Information

• Age/Sex: 35-year-old male
• Diagnosis: Treatment-resistant schizophrenia
• Current Medication: Clozapine 300 mg daily (duration on current dose)
• Previous antipsychotic trials: Document at least 2 failed adequate trials 1

Baseline Assessment (Pre-Clozapine)

• Baseline ECG findings:
  • Heart rate: ___ bpm
  • QTc interval: ___ ms (normal <450 ms in males)
  • Rhythm: Regular sinus rhythm
  • Any abnormalities: None/specify
• Baseline vital signs: BP / mmHg, HR ___ bpm
• Baseline troponin: ___ ng/L (if obtained, normal <16 ng/L) 2

Current Visit Assessment

Vital Signs:

• Blood pressure: Supine / mmHg, Standing / mmHg (assess for orthostatic hypotension) 1
• Heart rate: ___ bpm (monitor for tachycardia >100 bpm) 3, 4
• Temperature: ___ °C (fever may indicate myocarditis) 3

Cardiac Symptom Review:

• Chest pain: Yes/No
• Palpitations: Yes/No
• Dyspnea: Yes/No
• Syncope or presyncope: Yes/No
• Exercise intolerance: Yes/No

Current ECG Findings:

• Date obtained: ___
• Heart rate: ___ bpm
• QTc interval: ___ ms (compare to baseline; pathologic prolongation >500 ms) 1, 5
• Rhythm: Regular/irregular
• ST-segment changes: Present/absent
• T-wave abnormalities: Present/absent
• New findings compared to baseline: Yes/No, specify

Laboratory Results

Hematologic Monitoring (per REMS protocol):

• WBC: ___ /mm³ (must be >3,500/mm³) 1
• ANC: ___ /mm³ (must be >1,500/mm³) 1
• Monitoring frequency: Weekly for first 6 months, then biweekly 1

Cardiac Biomarkers (if obtained):

• Troponin: ___ ng/L (elevation may indicate myocarditis, especially in first 4 weeks) 3, 4
• CRP: ___ mg/L (elevation suggests inflammation) 3, 4
• CPK: ___ U/L (if obtained) 4

Metabolic Panel:

• Liver enzymes (AST/ALT): ___ U/L 1
• Electrolytes (K+, Mg2+, Ca2+): Within normal limits/specify abnormalities

Clozapine Level (if obtained):

• Plasma concentration: ___ ng/mL (therapeutic range 350-600 ng/mL) 6

Psychiatric Status

• Target symptoms: Document current positive/negative symptoms
• Treatment response: Improved/stable/worsened since last visit
• Medication adherence: Confirmed by pill count/pharmacy records 6

Assessment and Plan

ECG Interpretation:

• QTc change from baseline: +/- ___ ms
• Clinical significance: Benign/requires monitoring/concerning 5
• Action: If QTc >500 ms or increase >60 ms from baseline, consider dose reduction or cardiology consultation 1, 7

Cardiac Risk Assessment:

• Orthostatic hypotension: Present/absent (common, especially during titration) 1
• Tachycardia: Present/absent (occurs in >40% of patients) 3
• Signs of myocarditis: None/present (typically occurs within first 4 weeks) 3, 4

Management Plan:

1. Continue clozapine 300 mg daily (or adjust dose if indicated)
2. Next ECG: Specify timing based on findings
   • Routine monitoring: Every 6-12 months if stable 8
   • More frequent if QTc prolongation or cardiac symptoms present
3. Laboratory monitoring:
   • WBC/ANC per REMS schedule 1
   • Consider troponin/CRP if within first 4 weeks or new cardiac symptoms 3, 4
4. Vital signs: Monitor at each visit, especially orthostatic measurements
5. Patient education: Avoid QT-prolonging medications (www.crediblemeds.org) 7
6. Cardiology referral: If indicated for QTc >500 ms, new cardiac symptoms, or troponin elevation 3, 4

Common Pitfalls to Avoid

• Do not discontinue clozapine prematurely for mild ECG changes without cardiology input 5
• Recognize that tachycardia is common (>40% of patients) and often benign 3
• Monitor for myocarditis systematically in first 4 weeks with troponin/CRP if available 3, 4
• Document baseline ECG before initiation (completed in only 80% of cases in audits) 3
• Assess medication adherence before attributing symptoms to treatment resistance 6

Signature: _________________
Date: _________________

---

This template prioritizes safety monitoring while recognizing that most ECG abnormalities with clozapine are benign and should not prevent continuation of this highly effective medication for treatment-resistant schizophrenia 1, 9, 5.